Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

Date and time:
28.09.2021 at 17:40 - 18:40 CEST
Corporate Event
Kim Connelly; Subodh Verma; Ildiko Lingvay;
European Association for the Study of Diabetes (EASD)
Industry session on the occasion of the 57th Annual Meeting of the European Association for the Study of Diabetes. Obesity is a serious and growing health concern worldwide. It is a chronic disease associated with many health complications including a significant risk of developing CVD with increase in cardiovascular (CV) risk factors such as increased blood pressure, lipid levels and glucose levels. The link between obesity and CVD is well established and several studies have shown that weight loss improves CV risk factors and risk of CV events. Cardiovascular outcome trials (CVOTs) with glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in type 2 diabetes (T2D) have shown that some GLP‐1 RAs may reduce CV risk in adults with T2D and CVD. Novo Nordisk is pleased to introduce a symposium on “A STEP forward: Weight loss and improved cardiovascular risk factors”. This symposium aims to show the link between body weight, weight loss and CV outcomes, present key data from global phase 3 Semaglutide Treatment Effect in People with Obesity (STEP) program, evaluating the effects of s.c. once weekly semaglutide 2.4 mg in people with overweight or obesity, including weight loss and CV risk factors and discuss clinical trials exploring semaglutide in specific CV settings. We are delighted to welcome Dr. Kim A Connelly to host/chair the symposium with a brief introduction to the link between obesity, weight loss and CV risk. We also welcome Dr. Ildiko Lingvay to provide an overview of results of STEP trials, focusing on CV risk factors and Prof. Subodh Verma to discuss the implications of the STEP CV results and future trials in different CV settings. The symposium will conclude with a live panel discussion, allowing the audience to engage with the faculty during a question and answer session. Please join us virtually on 28 Sep 2021, 17:40-18:40 CET to learn about recent developments in obesity and CVD.

Introduction: obesity, weight loss and CV risk

STEPping forward: cardiovascular risk factors in patients with overweight or obesity

STEPping into the future: managing cardiovascular outcomes in people with overweight or obesity

Live Q&A

Kim Connelly - Speaker

Kim Connelly

St. Michael’s Hospital, Toronto, Canada

Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally & internationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. His work has been recognized evident by winning the “Young Investigator of the Year Award” by the Canadian Cardiovascular Society, an Early Researcher Award in 2014, and a CIHR New Investigator award in 2014.


Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He developed the first hemodynamically validated model of diabetes induced HFpEF. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses regenerative cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He has research support from the HSF of Canada, CIHR and CFI along with research support from the pharmaceutical industry. His work has been published in journals such as the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes. His H index is 41, and I index of 125.


Dr Connelly is immediate past president of the Canadian Society of Cardiac Magnetic resonance imaging. He runs a translational imaging laboratory and uses hyperpolarized C13 metabolic imaging to understand metabolism in the human heart in real time, as well as CMR to understand the impact of exercise upon cardiac remodeling. He was senior author of the EMPA HEART study along with Dr Verma and Zinman to assess the mechanism by which the SGLT2i empagliflozin provided cardiac protection in patients with type 2 DM. Finally, he was past section lead of 2018 macrovascular complications section for the Diabetes Canada Clinical practice updates and is current chair of the Canadian Cardiovascular Society guidelines.


Read full bio
Ildiko Lingvay - Speaker

Ildiko Lingvay

Southwestern Medical Center, Dallas, USA

Ildiko Lingvay is Professor in the Division of Endocrinology and the Department of Population and Data Sciences at the University of Texas (UT) Southwestern Medical Center in Dallas, TX, USA. She also serves as Medical Director of the Office of Clinical Trials Management overseeing the institutional review and approval of all clinical studies and clinical trials at UT Southwestern. She sees patients at the university clinics and hospital, as well as at the Parkland Health System.

Dr Lingvay leads a clinical research programme in the field of obesity, diabetes and associated metabolic complications with the ultimate goal of improving the lives of all patients who suffer from the many health consequences of these conditions. Her research interests span the spectrum from pathophysiology of the disease to comparative effectiveness of therapeutic approaches. She has participated in many clinical trials in the field and has a special interest in cardiovascular trials in diabetes and obesity.  She has published over 100 manuscripts in major medical journals and has contributed to several diabetes textbooks. She is an active member of the American Diabetes Association, where she served on the Scientific Sessions Organizing Committee and currently is on the grant review committee and a board member of the WIN ADA and Focus on Fellows initiatives.

Read full bio
Sumbodh Verma - Speaker

Subodh Verma

St. Michael’s Hospital, Toronto, Canada

Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr Verma was recently awarded the 2021 Lister Prize in Surgery from the University of Toronto in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr Verma has an hindex of 100 and his work has been cited over 50,000 times.

Dr Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr Verma has served in various capacities on the American Heart Association Councilon Cardiovascular Surgery and Anesthesia since 2008.

Dr Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.


Dr Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.

Read full bio